FASENRA Market Size, Forecast, and Market Insight - 2032

"FASENRA Market Size, Forecast, and Market Insight - 2032" report provides comprehensive insights about FASENRA for Asthma in the seven major markets. A detailed picture of the FASENRA for Asthma in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the FASENRA for Asthma. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the FASENRA market forecast analysis for Asthma in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in Asthma.

Drug Summary:

FASENRA (benralizumab) is a monoclonal antibody that binds directly to the IL-5 receptor alpha on eosinophils and attracts natural killer cells to induce rapid and near-complete depletion of eosinophils via apoptosis (programmed cell death). FASENRA is AstraZeneca's first respiratory biologic, approved as an add-on maintenance treatment in severe eosinophilic asthma in the US, EU, Japan, and other countries, with further regulatory reviews ongoing.

FASENRA injection is sterile, preservative-free, clear to opalescent, colorless to slightly yellow solution for SC injection. The IL-5 receptor is expressed on the surface of eosinophils and basophils. Benralizumab is produced in Chinese hamster ovary cells by recombinant DNA technology and has a molecular weight of approximately 150 kDa.

• Dosage and administration

The recommended dose of FASENRA is 30 mg administered once every 4 weeks for the first three doses and then once every 8 weeks thereafter by SC injection into the upper arm, thigh, or abdomen; 30 mg/mL solution of FASENRA in a single-dose prefilled syringe. FASENRA is clear to opalescent, colorless to a slightly yellow solution, and may contain a few translucent or white to off-white particles; FASENRA is for SC use only.

FASENRA should be administered by a healthcare professional. In line with clinical practice, monitoring patients after administering biologic agents is recommended. Before administration, warm FASENRA by leaving the carton at room temperature for about 30 min. Administer FASENRA within 24 h or discard it into a sharp container.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the FASENRA description, mechanism of action, dosage and administration, research and development activities in Asthma.
• Elaborated details on FASENRA regulatory milestones and other development activities have been provided in this report.
• The report also highlights the FASENRA research and development activities in Asthma across the United States, Europe, and Japan.
• The report also covers the patents information with expiry timeline around FASENRA.
• The report contains forecasted sales of FASENRA for Asthma till 2032.
• Comprehensive coverage of the late-stage emerging therapies for Asthma.
• The report also features the SWOT analysis with analyst views for FASENRA in Asthma.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

FASENRA Analytical Perspective by DelveInsight

• In-depth FASENRA Market Assessment

This report provides a detailed market assessment of FASENRA for Asthma in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2024 to 2032.

• FASENRA Clinical Assessment

The report provides the clinical trials information of FASENRA for Asthma covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for Asthma is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence FASENRA dominance.
• Other emerging products for Asthma are expected to give tough market competition to FASENRA and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of FASENRA in Asthma.
• Our in-depth analysis of the forecasted sales data of FASENRA from 2024 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the FASENRA in Asthma.

Key Questions:

• What is the product type, route of administration and mechanism of action of FASENRA?
• What is the clinical trial status of the study related to FASENRA in Asthma and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the FASENRA development?
• What are the key designations that have been granted to FASENRA for Asthma?
• What is the forecasted market scenario of FASENRA for Asthma?
• What are the forecasted sales of FASENRA in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to FASENRA for Asthma?
• Which are the late-stage emerging therapies under development for the treatment of Asthma?